Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
about
Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction.New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients.Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections
P2860
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Recombinant human hyaluronidas ...... cacy, safety and tolerability.
@en
type
label
Recombinant human hyaluronidas ...... cacy, safety and tolerability.
@en
prefLabel
Recombinant human hyaluronidas ...... cacy, safety and tolerability.
@en
P2093
P2860
P356
P1433
P1476
Recombinant human hyaluronidas ...... cacy, safety and tolerability.
@en
P2093
David Gelmont
Heinz Leibl
Isaac Melamed
Jennifer Doralt
Jennifer Puck
Lisa Kobrynski
Marlies Sharkhawy
Richard L Wasserman
Sudhir Gupta
P2860
P304
P356
10.2217/IMT-2016-0066
P577
2016-07-28T00:00:00Z